In addition to the results, Roche also announced that the US Food and Drug Administration (FDA) has accepted the company’s ...

Liza M. Cohen, MD, explains when to use CT vs MRI in thyroid eye disease and why to review images yourself.

Koreishi, MD, explains why inflammation control and planning are key to cataract surgery for patients with uveitis.

Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.

The US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee will meet October 30, 2026, to ...

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...

David F. Chang, MD, explained how offering complementary refractive IOLs reduces patient anxiety and indecision.

Vaidehi Dedania, MD, shared what the first whole eye transplant revealed about reperfusion, retinal cells, and sight. Dedania ...

The course is designed for comprehensive and pediatric ophthalmologists and optometrists, who often see patients with new ...

Kenneth C. Fan, MD, MBA, shared 4-year REMAIN data showing durable vision gains with MCO-010 in retinitis pigmentosa.

MOGAD more commonly presents with bilateral optic neuritis and more disc edema at onset, Chen said, with substantial optic ...

When people ask how I define a successful premium IOL outcome, they usually expect a number. The honest answer is that a ...